Portfolio company
Granza Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
4 investors
Sectors
About
This deep-tech company develops attack particle medicines to treat patients with cancer, autoimmune diseases and infections.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
ParcelBio
This deep-tech firm develops mRNA delivery technologies and programmable medicines for biotechnology and pharmaceutical organisations to treat autoimmune diseases and oncology.
Kodikaz Therapeutic Solutions
This deep-tech company develops a non-viral delivery platform for cell-specific gene therapies to treat cancer patients.
GenEdit
This deep-tech firm develops polymer nanoparticle delivery systems for genetic medicines to treat autoimmune diseases for the pharmaceutical and biotechnology industries.
Phost'in Therapeutics
This deep-tech company develops small molecule glycocalyx modifiers to treat patients with aggressive solid tumours by restoring immune responses against cancer cells.
EditForce
This deep-tech firm develops RNA editing tools and therapies for pharmaceutical, industrial, and agricultural organisations to treat diseases and manipulate genes.
GC Therapeutics
This deep-tech company develops a cell programming platform to produce off-the-shelf medicines for patients with gastrointestinal, neurological and immunological diseases.
Catena Biosciences
This deep-tech company develops protein conjugation technology and multi-payload conjugates to create targeted therapeutics for patients with oncology and autoimmune diseases.
Type6 Therapeutics
This deep-tech company develops kinase inhibitors for cancer treatment, intercepting enzymes in their inactive states to address drug resistance for patients with aggressive tumours.